The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study

Alimentary Pharmacology & Therapeutics
K D BardhanG Short

Abstract

The post-withdrawal characteristics of tegaserod treatment in patients with irritable bowel syndrome with constipation remain undefined. To evaluate the effects of continuous tegaserod treatment, versus intermittent or withdrawal of treatment in patients with irritable bowel syndrome with constipation. In a randomized, open-label trial, all patients initially received tegaserod 6 mg b.d. Responders were randomized to continue or withdraw from treatment for 8 weeks and symptom recurrence was assessed. Tegaserod was re-introduced in withdrawal patients who experienced symptom recurrence, allowing an assessment of intermittent treatment. Two separate analyses assessed the effects of intermittent and withdrawal of treatment on symptom recurrence. Five hundred irritable bowel syndrome with constipation patients initially received tegaserod; 410 completed treatment. Time to symptom recurrence was shorter in withdrawal patients than those maintained on tegaserod. Significantly more patients maintained on tegaserod had not experienced symptom recurrence by week 8, compared with intermittent (86.5% vs. 58.1%, respectively) or withdrawal of treatment (69.2% vs. 11.3%, respectively) (P < 0.0001 for both). Significant treatment effects wer...Continue Reading

References

May 1, 1992·Journal of Gastroenterology and Hepatology·I C Roberts-ThomsonD B Frewin
Apr 1, 1991·Gastroenterology·J E Everhart, P F Renault
Feb 17, 1990·BMJ : British Medical Journal·L J O'DonnellK W Heaton
Jan 1, 1986·Gut·P J WhorwellC T Roberts
Jan 21, 1995·BMJ : British Medical Journal·M J Farthing
Dec 24, 1997·Lancet·P R MaxwellD Kumar
Jun 6, 1998·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·C Mathis, C H Malbert
Feb 5, 1999·Health News·S J Bickston
Aug 3, 1999·Alimentary Pharmacology & Therapeutics·E A MayerL Chang
Aug 24, 1999·Gut·W G ThompsonS A Müller-Lissner
Aug 24, 1999·Gut·S J Veldhuyzen van ZantenA R Zinsmeister
Dec 2, 1999·Baillière's Best Practice & Research. Clinical Gastroenterology·M J Farthing
Nov 30, 2000·Current Treatment Options in Gastroenterology·A Wald
Jun 16, 2001·The New England Journal of Medicine·B J Horwitz, R S Fisher
Jun 14, 2002·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·A SchikowskiP Enck
Sep 25, 2002·Alimentary Pharmacology & Therapeutics·G TougasM A Rojavin
Oct 31, 2002·Gastroenterology·Lin Chang, Margaret M Heitkemper

❮ Previous
Next ❯

Citations

Jan 13, 2005·Alimentary Pharmacology & Therapeutics·S Müller-LissnerH Löffler
Mar 25, 2008·Therapeutics and Clinical Risk Management·Peter LayerAndreas Kreiss
Jan 1, 2006·Women's Health·Richard Saad, William D Chey
Oct 24, 2007·Gastroenterology Clinics of North America·Elizabeth J Videlock, Lin Chang
Sep 23, 2016·Gut·Cian McGuireDavid C Bulmer
Sep 2, 2016·F1000Research·Klaus BielefeldtSalman Nusrat
Aug 23, 2020·Gut·Jeremy M D NightingaleUNKNOWN Small Bowel and Nutrition Committee and the Neurogastroenterology and Motility Committee of the British Society of Gastroent
Oct 19, 2007·The Cochrane Database of Systematic Reviews·B W EvansP J Whorwell
Sep 14, 2019·Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry·Valentina Noemi MadiaRoberto Di Santo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.